Four Years After Covid-19 Success, mRNA Vaccines Aren’t Ready for Bird Flu
While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.
Personalis stock price target cut to $8 by H.C. Wainwright
H.C. Wainwright revised its price target for Personalis (NASDAQ:PSNL) shares, dropping it to $8.00 from the previous $11.00. Despite this reduction, the firm maintained a Buy rating on the company's ...